Press releases
- Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.56 |
---|---|
High | 36.56 |
Low | 36.56 |
Bid | 37.09 |
Offer | 37.30 |
Previous close | 36.56 |
Average volume | -- |
---|---|
Shares outstanding | 124.20m |
Free float | 118.64m |
P/E (TTM) | -- |
Market cap | 3.13bn USD |
EPS (TTM) | -4.24 USD |
Data delayed at least 15 minutes, as of May 05 2023.
More ▼